Developing antiepileptogenic drugs for acquired epilepsy: Targeting the mammalian target of rapamycin (mTOR) pathway

Keyphrases

• Mammalian Target of Rapamycin Pathway 100%
• Acquired Epilepsy 100%
• Antiepileptogenic 100%
• Anti-epileptogenic Drugs 100%
• Epilepsy 83%
• Epileptogenesis 83%
• Mammalian Target of Rapamycin (mTOR) 50%
• Brain Injury 50%
• Tuberous Sclerosis Complex 33%
• Kainate 33%
• Rapamycin 33%
• MTOR Inhibitor 33%
• Therapeutic Target 16%
• Cell Behavior 16%
• Seizure 16%
• Drug Development 16%
• Disease-modifying Therapy 16%
• Primary Cells 16%
• Synaptic Plasticity 16%
• Cell Signaling Pathways 16%
• Programmed Cell Death 16%
• Ion Channel Expression 16%
• Popular 16%
• Genetic Epilepsy 16%
• Limbic Seizures 16%
• Status Epilepticus 16%
• Translational Application 16%
• Modeling Data 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Mammalian Target of Rapamycin 100%
• Epileptogenesis 100%
• Brain Injury 60%
• Rapamycin 40%
• Mammalian Target of Rapamycin Inhibitor 40%
• Kainic Acid 40%
• Tuberous Sclerosis 40%
• Drug Development 20%
• Ion Channel 20%
• Programmed Cell Death 20%
• Epileptic State 20%
• Diseases 20%

Neuroscience

• Mammalian Target of Rapamycin 100%
• Epileptogenesis 71%
• Tuberous Sclerosis 28%
• Sirolimus 28%
• Cell Death 14%
• Cell Signaling 14%
• Cell Function 14%
• Ion Channel 14%
• Synaptic Plasticity 14%
• Status Epilepticus 14%